XP
XP0.F Xenon Pharmaceuticals Inc
- Market cap
- EUR 3.60B
- P/E
- -
- P/B
- 3.52x
- ROE
- -37.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is XP0.F undervalued?
Graham numberThe Graham number of Xenon Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Xenon Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Xenon Pharmaceuticals Inc yet.
Xenon Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric di…
Full company profileXenon Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Xenon Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.80M | 311K | 0.00 | 6.83M | 32.2M | 18.4M | 9.43M | 0.00 | 0.00 | 7.50M | 0.00 |
| Gross Profit | - | - | -6.00M | 6.83M | - | - | - | - | - | - | - |
| Operating Income | -24.8M | -32.6M | -38.0M | -42.8M | -31.3M | -79.0M | -129M | -214M | -279M | -373M | -474M |
| EBITDA | - | -31.9M | -32.5M | -39.8M | -28.0M | -78.0M | -128M | -212M | -277M | -371M | -472M |
| Net Income | -23.0M | -30.7M | -34.5M | -41.6M | -28.8M | -78.9M | -125M | -182M | -234M | -346M | -431M |
| EPS | - | -1.71 | -1.34 | -1.48 | -0.82 | -1.53 | -2.00 | -2.42 | -3.07 | -4.32 | -4.39 |
| Balance Sheet | |||||||||||
| Total Assets | 67.5M | 46.1M | 122M | 148M | 189M | 572M | 754M | 965M | 798M | 633M | 1.20B |
| Total Liabilities | 3.59M | 10.2M | 19.1M | 55.7M | 17.8M | 22.0M | 32.6M | 36.9M | 43.2M | 51.4M | 53.5M |
| Shareholders' Equity | 63.9M | 35.9M | 103M | 92.0M | 171M | 550M | 721M | 928M | 755M | 582M | 1.15B |
| Cash & Short-term Investments | 17.1M | 20.5M | 67.8M | 24.8M | 45.0M | 176M | 57.2M | 149M | 143M | 199M | 82.6M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -19.6M | -28.7M | -34.7M | -4.71M | -48.1M | -69.5M | -98.4M | -151M | -181M | -279M | -366M |
| Capital Expenditure | 279K | 315K | 507K | 1.24M | 2.64M | 2.05M | 2.89M | 5.62M | 3.08M | 799K | 923K |
| Free Cash Flow | - | -29.0M | -35.2M | -5.87M | -50.8M | -71.6M | -101M | -157M | -184M | -280M | -367M |
| Ratios | |||||||||||
| ROE | -36.0% | -85.4% | -33.4% | -45.2% | -16.8% | -14.3% | -17.4% | -19.7% | -31.0% | -59.5% | -37.6% |
| ROA | -34.1% | -66.6% | -28.2% | -28.2% | -15.2% | -13.8% | -16.6% | -18.9% | -29.4% | -54.6% | -35.9% |
| Net Profit Margin | -1,275.5% | -9,872.7% | - | -609.1% | -89.7% | -427.8% | -1,328.9% | - | - | -4,612.1% | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Xenon Pharmaceuticals Inc dividends
Xenon Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Who owns Xenon Pharmaceuticals Inc
- Insiders 0.16%
- Institutions 99.84%
- Public & others 0.00%
- Shares outstanding 98.3M
- Free float 92.3M
Xenon Pharmaceuticals Inc company profile
- Company name
- Xenon Pharmaceuticals Inc
- Ticker
- XP0.F
- ISIN
- CA98420N1050
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 358
- Fiscal year end
- December
- Address
- 200-3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8
- Phone
- 604 484 3300
- Website
- xenon-pharma.com
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.
Xenon Pharmaceuticals Inc management
10- Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.President, CEO & Director · born 1976
- Mr. Thomas Patrick Kelly J.D.Chief Financial Officer · born 1971
- Ms. Andrea DiFabio J.D.Chief Legal Officer & Corporate Secretary · born 1968
- Dr. Christopher John Kenney M.D.Chief Medical Officer · born 1971
- Mr. Darren S. Cline M.B.A.Chief Commercial Officer · born 1964
- Dr. Matthew D. Ronsheim Ph.D.Chief Operating Officer · born 1972
- Ms. Shelley McCloskey B.A.Executive Vice President of Human Resources · born 1960
- Dr. Robin P. Sherrington Ph.D.Executive Vice President of Strategy & Innovation · born 1961
- Dr. James R. Empfield Ph.D.Executive Vice President of Drug Discovery · born 1961
- Ms. Colleen AlabisoSenior Vice President of Corporate Affairs